Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the real-world use of ruxolitinib in patients with myelofibrosis (MF) who had anemia or thrombocytopenia in US community practices. Overall, it has been shown that the use of ruxolitinib in these patients leads to good control of spleen size and symptoms. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.